Overview

Hepatocellular Carcinoma (HCC) Transarterial Chemoembolisation (TACE) +Axitinib

Status:
Completed

Trial end date:
2018-06-07

Target enrollment:

Participant gender:

Summary

The survival of subjects with unresectable hepatocellular carcinoma (HCC) receiving transarterial chemoembolization is improved with addition of axitinib.

Phase:

Phase 2

Details

Lead Sponsor:

Chinese University of Hong Kong

Treatments:

Axitinib